GH-Axis · Research Compound
CJC-1295
A growth-hormone-releasing hormone analog studied for growth-hormone-axis research, often paired with Ipamorelin.
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), studied for its ability to stimulate growth-hormone release. It exists in forms with and without DAC (Drug Affinity Complex), which affects half-life. In research it is the most referenced GHRH-analog component of the classic CJC-1295 + Ipamorelin pairing.
Research interest focuses on the GH-axis: how a GHRH analog influences growth-hormone pulse amplitude and downstream IGF-1. As with the other peptides in this category, the data are largely preclinical and CJC-1295 is not approved for human use.
Research areas
GHRH-Analog Mechanism
Binds GHRH receptors to stimulate growth-hormone release; the DAC variant extends half-life substantially.
GH-Pulse & IGF-1
Research examines effects on growth-hormone pulse amplitude and IGF-1 levels.
Combination Research
The classic pairing with Ipamorelin (a GHRP) is the most-referenced GHRH-analog + GHRP research pairing in the literature.
Metabolic Models
Studied in metabolic research contexts.
Recent research findings
- 2024Continued research on GHRH-analog pharmacokinetics and the DAC vs. no-DAC distinction.
- 2023Reviews characterized the combined activity of GHRH-analog plus GHRP in research.
- 2022Studies refined understanding of GH-pulse dynamics from analog administration.
Published Research & Citations
The research summarized above is drawn from published, peer-reviewed studies. Explore the 5 sources below — links open the abstract or, where marked, the full free article on the U.S. National Library of Medicine (PubMed / PMC).
- Jette L, et al. hGRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. Foundational study identifying CJC-1295 as a long-acting GHRH analog via albumin binding.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006. Human study showing sustained GH and IGF-I elevation after CJC-1295 administration.
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 2006. Found GH pulsatility is preserved while baseline GH and overall secretion rise.
- Alba M, et al. Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism, 2006. Animal study showing restored growth with once-daily dosing.
- Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 2009. Human study characterizing downstream GH/IGF-1 axis and serum protein changes.